MedPath

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

Phase 2
Terminated
Conditions
Endometrial Cancer
Registration Number
NCT00003179
Lead Sponsor
Gynecologic Oncology Group
Brief Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia.

PURPOSE: Phase II trial to compare the effectiveness of surgery alone with that of medroxyprogesterone followed by surgery in preventing endometrial cancer in patients who have endometrial hyperplasia.

Detailed Description

OBJECTIVES:

* Determine the joint occurrence of atypical hyperplasia and adenocarcinoma in patients diagnosed at initial biopsy to have complex atypical hyperplasia.

* Compare the histologic response rates in patients with atypical endometrial hyperplasia treated with oral medroxyprogesterone acetate (Provera) vs intramuscular medroxyprogesterone acetate suspension (Depo-Provera) .

OUTLINE: This is a randomized, two-part study.

* Part A: Patients undergo immediate hysterectomy.

* Part B: Patients are randomized to 1 of 2 arms.

* Arm I: Patients receive oral medroxyprogesterone acetate (Provera) once daily for 3 months.

* Arm II: Patients receive medroxyprogesterone acetate suspension (Depo- Provera) intramuscularly once monthly for 3 months (days 1, 31, and 62).

Patients undergo hysterectomy at the end of the third month.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A minimum of 360 patients for part A and 140 patients (70 per arm) for part B will be accrued for this study.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
360
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (31)

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Community Hospital of Los Gatos

🇺🇸

Los Gatos, California, United States

Chao Family Comprehensive Cancer Center

🇺🇸

Orange, California, United States

Walter Reed Army Medical Center

🇺🇸

Washington, District of Columbia, United States

University of Chicago Cancer Research Center

🇺🇸

Chicago, Illinois, United States

Indiana University Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Holden Comprehensive Cancer Center

🇺🇸

Iowa City, Iowa, United States

Albert B. Chandler Medical Center, University of Kentucky

🇺🇸

Lexington, Kentucky, United States

Marlene and Stewart Greenebaum Cancer Center, University of Maryland

🇺🇸

Baltimore, Maryland, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

🇺🇸

Baltimore, Maryland, United States

Scroll for more (21 remaining)
Arizona Cancer Center
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.